KR102143887B1 - Toso 활성을 조절하기 위한 방법 및 조성물 - Google Patents

Toso 활성을 조절하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102143887B1
KR102143887B1 KR1020147028977A KR20147028977A KR102143887B1 KR 102143887 B1 KR102143887 B1 KR 102143887B1 KR 1020147028977 A KR1020147028977 A KR 1020147028977A KR 20147028977 A KR20147028977 A KR 20147028977A KR 102143887 B1 KR102143887 B1 KR 102143887B1
Authority
KR
South Korea
Prior art keywords
ser
val
thr
pro
leu
Prior art date
Application number
KR1020147028977A
Other languages
English (en)
Korean (ko)
Other versions
KR20150003197A (ko
Inventor
마이클 더블유. 투슈
탁 더블유. 막
파멜라 에스. 오하시
필립 랑
칼 랑
더크 브래너
글로리아 린
Original Assignee
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 헬스 네트워크 filed Critical 유니버시티 헬스 네트워크
Publication of KR20150003197A publication Critical patent/KR20150003197A/ko
Application granted granted Critical
Publication of KR102143887B1 publication Critical patent/KR102143887B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
KR1020147028977A 2012-03-16 2013-03-14 Toso 활성을 조절하기 위한 방법 및 조성물 KR102143887B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261612183P 2012-03-16 2012-03-16
US61/612,183 2012-03-16
US201261646143P 2012-05-11 2012-05-11
US61/646,143 2012-05-11
US201261731428P 2012-11-29 2012-11-29
US61/731,428 2012-11-29
PCT/IB2013/001179 WO2013136193A2 (fr) 2012-03-16 2013-03-14 Procédés et compositions pour moduler l'activité toso

Publications (2)

Publication Number Publication Date
KR20150003197A KR20150003197A (ko) 2015-01-08
KR102143887B1 true KR102143887B1 (ko) 2020-08-12

Family

ID=48747619

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028977A KR102143887B1 (ko) 2012-03-16 2013-03-14 Toso 활성을 조절하기 위한 방법 및 조성물

Country Status (9)

Country Link
US (5) US9228006B2 (fr)
EP (2) EP3626254A1 (fr)
JP (3) JP6200437B2 (fr)
KR (1) KR102143887B1 (fr)
CN (1) CN104394880B (fr)
AU (3) AU2013234046B2 (fr)
CA (1) CA2867444C (fr)
IL (1) IL234683B (fr)
WO (1) WO2013136193A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
CA2917077A1 (fr) 2013-07-03 2015-01-08 University Health Network Anticorps anti-toso
EP3741390A1 (fr) 2014-01-15 2020-11-25 Medlmmune, LLC Anticorps spécifique du rsv et parties fonctionnelles de ceux-ci
AU2015225867B2 (en) * 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
EP3009841A1 (fr) * 2014-10-14 2016-04-20 Bernhard-Nocht-Institut für Tropenmedizin Détection des anticorps à l'aide d'un complexe immunitaire amélioré ELISA
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3098237B1 (fr) * 2015-05-28 2018-08-01 Universität Zu Köln Récepteur d'antigène chimérique anti-toso et son utilisation
TW202035461A (zh) * 2019-02-15 2020-10-01 大學醫療網路 Ｆｃｍｒ結合分子及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727350B2 (en) 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (fr) 1987-02-17 1998-04-01 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2100892T3 (es) * 1989-09-15 1997-07-01 Tanox Biosystems Inc Tratamiento de enfermedades autoinmunitarias.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2116764C (fr) 1991-09-13 1999-12-07 Amy J. Weiner Compositions de polypeptides du virus de l'hepatite c immunoreactives
JPH07501694A (ja) * 1991-11-18 1995-02-23 タノックス　バイオシステムズ　インコーポレイテッド 免疫グロブリン生産のアイソタイプ特異的抑制のためのアンチセンスオリゴヌクレオチド
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
CA2507749C (fr) 1991-12-13 2010-08-24 Xoma Corporation Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6555314B1 (en) 1998-03-30 2003-04-29 Rigel Pharmaceuticals, Inc. Toso as a target for drug screening
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2002541195A (ja) * 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
NZ521437A (en) * 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
MXPA03002049A (es) 2000-09-08 2003-07-24 Schering Corp Genes de mamiferos: reactivos y metodos relacionados.
CA2424977C (fr) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
EP2322200A3 (fr) * 2002-10-29 2011-07-27 Genentech, Inc. Les compositions et les methodes pour le traitement de maladies liées immunisées
EP1444989A1 (fr) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CN101875957A (zh) 2004-12-30 2010-11-03 新加坡科技研究局 中国仓鼠凋亡相关基因
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
SG174780A1 (en) * 2006-09-08 2011-10-28 Ambrx Inc Site specific incorporation of non-natural amino acids by vertebrate cells
CN101970472B (zh) * 2007-06-06 2013-10-30 研究发展基金会 Rtef-1变体及其用于抑制血管发生的用途
EP2291657B1 (fr) * 2008-05-01 2016-04-13 Zymogenetics, Inc. Concentrations sériques en hétérotrimères blys/april et utilisation dans des procédés de diagnostic
MX2012001999A (es) 2009-08-17 2012-02-29 Univ California Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2.
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727350B2 (en) 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG L ET AL, JOURNAL OF GENE MEDICINE, JOHN WI LEY & MSONS, INC, US vol . 7 , no. 3 , 1 March 2005 (2005-03-01) ,

Also Published As

Publication number Publication date
US20150139995A1 (en) 2015-05-21
US9624289B2 (en) 2017-04-18
US20150299292A1 (en) 2015-10-22
AU2013234046B2 (en) 2017-09-07
WO2013136193A2 (fr) 2013-09-19
CN104394880A (zh) 2015-03-04
WO2013136193A3 (fr) 2014-01-16
JP6200437B2 (ja) 2017-09-20
JP6744391B2 (ja) 2020-08-19
AU2017272172B2 (en) 2019-04-04
JP2015511599A (ja) 2015-04-20
IL234683B (en) 2020-02-27
US9228006B2 (en) 2016-01-05
US9321824B2 (en) 2016-04-26
WO2013136193A8 (fr) 2014-05-08
EP2825191A2 (fr) 2015-01-21
EP3626254A1 (fr) 2020-03-25
JP6462800B2 (ja) 2019-01-30
AU2019204594B2 (en) 2021-05-06
AU2013234046A1 (en) 2014-10-09
IL234683A0 (en) 2014-11-30
US20180016320A1 (en) 2018-01-18
AU2019204594A1 (en) 2019-07-18
CA2867444C (fr) 2021-04-13
US10822388B2 (en) 2020-11-03
US9670265B2 (en) 2017-06-06
JP2018027951A (ja) 2018-02-22
EP2825191B1 (fr) 2019-08-28
KR20150003197A (ko) 2015-01-08
JP2019054821A (ja) 2019-04-11
US20150197551A1 (en) 2015-07-16
CN104394880B (zh) 2020-08-28
CA2867444A1 (fr) 2013-09-19
AU2017272172A1 (en) 2017-12-21
US20130281356A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
KR102143887B1 (ko) Toso 활성을 조절하기 위한 방법 및 조성물
JP6538707B2 (ja) 免疫応答を調節するための方法及び組成物
US7090843B1 (en) Recombinant anti-CD30 antibodies and uses thereof
KR101692080B1 (ko) 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
CN108367071A (zh) 用于癌症免疫疗法的nkg2d-ig融合蛋白
EA025962B1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO2010022175A1 (fr) Identification de la sortiline en tant que récepteur neuronal pour la protéine de la démence frontotemporale, la progranuline
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant